When a Cancer Staging Visit Also Comes With 'Your Heart Function Is 50%': How Cardiac Reserve Shapes Colorectal Cancer Treatment, and What to Sort Out Before the First Infusion

Hearing about an advanced cancer stage is hard enough. When the same visit adds a sentence like 'your heart doesn't pump as well as most people's — about 50 percent,' worry usually splits in two directions: the cancer itself, and whether treatment is even possible. These are handled by different specialties in different ways, which is why a single appointment rarely resolves both at once.

It helps to know what the number means. In most cases it refers to the left ventricular ejection fraction (LVEF) measured on an echocardiogram — the percentage of blood the left ventricle pushes out with each beat. The lower edge of the normal range is commonly described as somewhere around 50 to 55 percent. So 50 percent does not mean the heart is working at half capacity; it sits near the lower boundary of normal. The value also shifts by several points depending on who measures it, which method is used, and the person's blood pressure, heart rate, and fluid status that day. For that reason, clinicians usually care less about one isolated number and more about establishing a baseline and tracking change over time.

Cardiac function is checked before cancer treatment for three main reasons. First, the drugs. Fluoropyrimidines commonly used in colorectal cancer (5-FU, capecitabine) have been associated, uncommonly, with chest pain, coronary artery spasm, or rhythm disturbances — so when there is an underlying heart concern, it is safer to agree in advance on how symptoms will be reported from the very first cycle. Second, surgery and anesthesia. General anesthesia and abdominal surgery require the heart to tolerate blood loss, fluid shifts, and temperature changes, so cardiopulmonary reserve is assessed separately. Third, endurance across the whole treatment period: anemia, dehydration, electrolyte imbalance, and infection all increase the heart's workload, so these are monitored more closely in someone with reduced cardiac function.

Importantly, reduced heart function does not automatically translate to 'no treatment.' In practice, what gets adjusted is which agents are chosen, at what dose and interval, how often monitoring tests are inserted, and where surgery sits in the sequence. This is why two people with the same stage can end up with different plans.

Preoperative assessment typically starts with an ECG and an echocardiogram, with stress testing or coronary evaluation added when indicated. Clinicians often ask less about numbers and more about functional capacity in daily life: how many minutes you can walk on level ground without stopping, how many flights of stairs you can climb, whether you need extra pillows because lying flat makes you breathless. Writing down these three answers before the visit makes the conversation far more productive.

Once treatment starts, it is worth agreeing on home warning signs. Pressure or tightness in the chest, breathlessness at rest, needing to sleep propped up, ankle or shin swelling that leaves an indentation when pressed, a sudden weight gain of two to three kilograms or more over a few days, reduced urine output, fainting or graying vision — these generally belong in the 'call the same day' category rather than waiting for the next appointment. Ordinary cycle-related fatigue or appetite loss is usually recorded and reviewed at the next visit.

Many families also ask how an advanced cancer can be found with no symptoms at all. The colon and rectum are tube-shaped organs, and a lesion can grow considerably before the passage narrows enough to produce clear signals; bleeding may be too small in volume to notice. A symptom-free diagnosis is therefore not, by itself, evidence that something was overlooked. Frustration is a natural reaction, but the longer it is spent re-examining the past, the less energy remains for the schedule ahead.

A word about prognosis figures: survival statistics found online are averages drawn from large groups treated years earlier, and outcomes vary widely within the same stage depending on the number of involved lymph nodes, tumor location, treatment response, and other medical conditions. In locally advanced disease with lymph node involvement but no distant spread, it is not unusual for chemotherapy, radiation, and surgery to be sequenced with cure as the stated goal. Only the treating team, looking at imaging, pathology, and overall condition including the heart, can say which goal applies in a given case.

A practical order for the next appointment: confirm which test the 50 percent came from and when; ask whether a baseline cardiac study should be recorded before treatment begins; ask whether a cardiology consultation can be scheduled before the first infusion; request the name of the planned regimen, the total number of cycles, and written cardiac warning signs; and clarify how existing heart and blood pressure medications will be handled during treatment. With those five settled, a vague 'will she be cured?' becomes a question that can actually be answered.

This article is general information and does not replace individual medical care. All decisions about tests, medications, and surgery should be made in consultation with your treating clinicians.